Document Detail

Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
MedLine Citation:
PMID:  19581809     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Fecal calprotectin seems to have a diagnostic precision in predicting relapse in quiescent ulcerative colitis patients. However, the data remain controversial in Crohn's disease. The aim of this study was to prospectively evaluate the role of fecal calprotectin as a predictive marker for 1-year follow-up in patients with asymptomatic Crohn's disease. METHODS: Fifty-three Crohn's disease patients in clinical remission were consecutively included providing at the beginning of the study a single stool sample as well as a blood sample and regularly followed-up for 12 months. Fecal calprotectin level was measured using a commercially available enzyme-linked immunoassay. RESULTS: Among 53 patients, 10 (18.9%) developed clinical relapse during the 12-month follow-up period. Median fecal calprotectin level was significantly higher in relapse group patients compared with that in nonrelapse group (380.5 vs. 155 microg/g, P<0.001). With a cutoff value of 340 microg/g fecal calprotectin gave sensitivity of 80% and specificity of 90.7% in predicting clinical relapse. Fecal calprotectin level greater that 340 microg/g gave an 18-fold higher risk to develop relapse (log rank P<0.001) and was found to be an independent predictive factor of relapse (P=0.02). CONCLUSION: Fecal calprotectin seems to be a reliable marker of relapse in quiescent Crohn's disease patients.
Lamia Kallel; Imen Ayadi; Samira Matri; Monia Fekih; Nadia Ben Mahmoud; Moncef Feki; Sami Karoui; Bechir Zouari; Jalel Boubaker; Naziha Kaabachi; Azza Filali
Related Documents :
7847289 - Paradoxical response to heparin in 10 patients with ulcerative colitis.
7167739 - A quantitative method of estimating inflammation in the rectal mucosa. iii. chronic ulc...
18662289 - Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopur...
20629099 - Clinical variables as prognostic tools in pediatric-onset ulcerative colitis: a retrosp...
19288029 - Effect of mdr1 gene promoter methylation in patients with ulcerative colitis.
22033449 - Clinical and laboratory factors associated with the severity of proliferative sickle ce...
18298639 - Short-term treatment with infliximab in chronic refractory pouchitis and ileitis.
1392659 - Coughing as the sole symptom of occupational bronchial allergy.
9578049 - Celiac disease, bilateral occipital calcifications and intractable epilepsy: mechanisms...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  22     ISSN:  1473-5687     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-05     Completed Date:  2010-04-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  340-5     Citation Subset:  IM    
Department of Gastroenterology, Rabta Hospital, Jabbari 1007, Tunis, Tunisia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / metabolism
Chi-Square Distribution
Colon / metabolism*
Crohn Disease / diagnosis*,  metabolism,  therapy
Enzyme-Linked Immunosorbent Assay
Feces / chemistry*
Kaplan-Meiers Estimate
Leukocyte L1 Antigen Complex / metabolism*
Middle Aged
Predictive Value of Tests
Proportional Hazards Models
Prospective Studies
ROC Curve
Remission Induction
Risk Assessment
Sensitivity and Specificity
Time Factors
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Biological Markers; 0/Leukocyte L1 Antigen Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Breast cancer screening participation among Turks and Moroccans in the Netherlands: exploring reason...
Next Document:  Costs and Risks in the Management of Patients With Gastric Acid Hypersecretion.